注射用洛铂治疗中晚期鼻咽癌的研究进展  

Research progress of lobaplatin for advanced nasopharyngeal carcinoma

作　　者：陈丹君[1] 孙旭 乔进[3] 何侠[4] CHEN Dan-jun;SUN Xu;QIAO Jin;HE Xia(Department of Pharmacy,the First Affiliated Hospital of University of South China,Hengyang Hunan 421001 Guizhou Yibai Pharmaceutical Co.,Ltd,Guiyang 550008;Nantong Third People's Hospital,Nantong Jiangsu 226000;Jiangsu Cancer Hospital,Nanjing 210009)

机构地区：[1]南华大学附属第一医院药剂科,湖南衡阳421001 [2]贵州益佰制药股份有限公司,贵阳550008 [3]南通市第三人民医院,江苏南通226000 [4]江苏省肿瘤医院,南京210009

出　　处：《中南药学》2018年第12期1739-1742,共4页Central South Pharmacy

基　　金：贵阳市科技计划项目筑科合同[20151001]号

摘　　要：70%鼻咽癌患者在诊断时已是中晚期,根治性放疗配合化疗是中晚期鼻咽癌主要的治疗手段。顺铂是治疗中晚期鼻咽癌经典药物,但其严重的不良反应及治疗诱导性耐药等缺点限制其临床长期、广泛使用。第三代铂类抗肿瘤药物洛铂具有高效、低毒、不交叉耐药的特点,对于中晚期鼻咽癌,洛铂单药或联合其他化疗药物与放疗联用具有协同增敏的作用,疗效与顺铂方案疗效相当,耐受性更好,且与顺铂不交叉耐药,值得临床推广应用。About 70%patients with nasopharyngeal carcinoma (NPC)are in advanced stage when diagnosed. Radical radiotherapy combined with chemotherapy is the main treatment for advanced NPC.Cisplatin (DDP) is a classic first-line drug for advanced NPC.However,DDP brings severe adverse reactions and treatmentinduced drug resistance,so its long time clinical use has been limited.The third generation of platinum antitumor drug lobaplatin (LBP)shows high efficiency,low toxicity and no cross-resistance.LBP alone or LBP with other chemotherapeutic drugs in the radiotherapy has a synergistic sensitizing effect for advanced NPC, whose efficacy is almost the same as that of cisplatin-based regime,but with better tolerance.Moreover,it has no cross resistance with cisplatin,so it is good for clinical application.

关 键 词：鼻咽癌 洛铂 放化疗 

分 类 号：R979.1[医药卫生—药品]